Cancer-Associated Anorexia and Cachexia : Implications for Drug Therapy

Area of Science:

• Oncology
• Pharmacology
• Clinical Nutrition

Background:

• Cancer-associated anorexia and cachexia significantly impact patient well-being.
• Conventional treatments like chemotherapy and nutritional support often fail to reverse these conditions.
• Pharmacological interventions are being explored to manage cancer-related appetite loss and weight decline.

Purpose of the Study:

• To review the efficacy of various drugs in ameliorating cancer-associated anorexia and cachexia.
• To evaluate the potential of cyproheptadine, corticosteroids, and megestrol acetate.
• To discuss ongoing research into anabolic steroids and hydrazine sulfate.

Main Methods:

• Review of randomized clinical trials and preliminary evidence for drug efficacy.
• Analysis of studies investigating appetite stimulation and weight changes.
• Assessment of antiemetic properties and ongoing clinical trials.

Main Results:

• Cyproheptadine demonstrated minimal appetite stimulation without significant weight gain.
• Corticosteroids were shown to stimulate appetite but did not lead to substantial non-fluid weight gain.
• Megestrol acetate exhibited potent appetite stimulation and improved non-fluid body weight in advanced cancer patients, with preliminary antiemetic effects.

Conclusions:

• Megestrol acetate appears to be a promising agent for managing cancer anorexia/cachexia due to its effects on appetite and weight.
• Corticosteroids and cyproheptadine have limited efficacy in improving weight.
• Anabolic steroids and hydrazine sulfate require further investigation before clinical recommendations can be made.